Brief: Ambu Q3 EBIT Before Special Items In Line With Prelim DKK 42 Million

Ambu A/S

25/08/2022 07:19

Aug 25 (Reuters) - Ambu A/S  AMBUb.CO :
    * INTERIM REPORT FOR Q3 2021/22
    * Q3 REVENUE DKK 1,128 MILLION VERSUS PRELIM NUMBER OF DKK
1,128
MILLION ANNOUNCED ON AUG 3
    * Q3 EBIT BEFORE SPECIAL ITEMS DKK 42 MILLION VERSUS PRELIM
NUMBER
OF DKK 42 MILLION ANNOUNCED ON AUG 3
    * AMBU MAINTAINS FINANCIAL GUIDANCE ANNOUNCED ON 3 AUGUST
2022
    * Q3 SALES OF ENDOSCOPES AT  400,000 UNITS VERSUS 386,000 
UNITS
YEAR AGO
    * SUCCESSFULLY ENTERED ENT IN FY 2018/19 AND CYSTOSCOPY IN
FY
2019/20, AND TOGETHER THEY WILL CONTRIBUTE 700,000+ ENDOSCOPES
THIS FISCAL YEAR
    * FOR NEW SEGMENTS, AMBU WILL ENTER INTO URETEROSCOPY AND
CHOLANGIOSCOPY, FOR WHICH THE SINGLE-USE MARKETS ALREADY EXIST,
AND COLONOSCOPY, WHERE AMBU WILL BE THE FIRST MOVER
    * DURING Q3 2021/22, AMBU SAW AN INCREASED IMPACT FROM THE
MACRO
ENVIRONMENT ON 2021/22 FINANCIALS, WITH A NEGATIVE IMPACT ON
GROSS MARGINS, DRIVEN PARTICULARLY BY INFLATIONARY EFFECTS ON
RAW MATERIALS AND COSTS OF LOGISTICS
    * THE WAR IN UKRAINE HAS NO DIRECT IMPACT ON AMBU, AS THE
BUSINESSES IN UKRAINE AND RUSSIA ARE VERY SMALL

Source text for Eikon:  ID:nGNE474YCW 
Further company coverage:  AMBUb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))